Inovio Pharmaceuticals (INO) Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals (INO) today and set a price target of $13. The company’s shares closed yesterday at $3.75, close to its 52-week low of $3.63.

Selvaraju commented:

“Our 12-month price target is derived from a market value of the firm at $1.4B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $70M debt. Investment risks include: (1) failure of VGX-3100 in clinical trials; (2) failure of VGX-3100 to secure regulatory approval; (3) failure of VGX-3100 to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential dilution risk.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, implying a 180.0% upside from current levels. In a report released yesterday, Maxim Group also assigned a Buy rating to the stock with a $8 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.30 and a one-year low of $3.63. Currently, Inovio Pharmaceuticals has an average volume of 1.05M.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2018, Avtar Dhillon, a Director at INO bought 25,000 shares for a total of $50,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts